Product Description
Aflibercept (EYLEA®), initially named VEGF Trap-eye, is the most recent anti-VEGF agent to be granted US Food and Drug Administration approval for the treatment of neovascular AMD. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689264/)
Mechanisms of Action: VEGF Antagonist
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: Bayer
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Iran, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 67
Highest Development Phases
Phase 3: Choroid Diseases|Dyslipidemia|Glaucoma, Neovascular|Macular Degeneration|Macular Edema|Melanoma|Neovascular age-related macular degeneration|Obstetric Labor, Premature|Other|Retinal Vein Occlusion|Retinopathy of Prematurity|Type 1 Diabetes|Type 2 Diabetes|Wet Macular Degeneration
Phase 2: Colorectal Cancer|Graves Disease|Graves Ophthalmopathy|Retinal Neovascularization|Thyroid Eye Disease|Uveal Melanoma
Phase 1: COVID-19|Malaria
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MCC-21341 | P2 |
Recruiting |
Uveal Melanoma |
2030-10-31 |
|
| BUTTERFLEYE NEXT | P3 |
Active, not recruiting |
Retinopathy of Prematurity |
2027-07-19 |
|
| KILAUEA | P3 |
Not yet recruiting |
Choroid Diseases|Macular Degeneration |
2026-09-01 |
52% |
| KILAUEA | P3 |
Not yet recruiting |
Choroid Diseases|Macular Degeneration |
2026-09-01 |
52% |
| PHOTONiC | P3 |
Recruiting |
Macular Edema |
2026-05-12 |